CGX Chromogenex

RNS Number:8705Y
Chromogenex PLC
25 June 2007


                                Chromogenex plc

                               New Product Launch


An advanced system designed to help people stop smoking has been launched by
AIM-listed medical and aesthetic laser device company Chromogenex. With the UK's
smoking in public places ban coming into effect on 1 July 2007, the Nicolite
laser has been introduced to meet the anticipated demand for such aids.


Nicolite is a laser system which uses a coherent beam of light of low power to
stimulate the release of endorphins by the body. Endorphins are the body's
natural painkillers and research suggests that endorphins also help to suppress
physical cravings such as the desire for nicotine.


Smoking cessation is a multi million pound market and reports suggest that with
the UK's new mandatory ban on smoking in public places the demand for smoking
cessation treatments will rise rapidly.


Peter McGuinness, Chairman of Chromoegenex, commented: 'Our Nicolite system will
be rolled out over the forthcoming months into the 1200 plus clinics  registered
to provide laser treatment in the UK. As well as servicing this rapidly growing
market  we also plan to sell the product internationally through our existing
distribution network.'


                                    - ends -

For further information:

Chromogenex plc                                 020 8434 0540
Peter McGuinness, Chairman                      07775 834 777

Blue Oar                                        020 7448 4400
Jerry Keen/Romil Patel

Threadneedle Communications                     020 7936 9605
Graham Herring/Josh Royston                     07793 839 024


Notes to Editors:


Chromogenex plc is a profitable and established medical and aesthetic laser
device company that joined AIM, part of the London Stock Exchange in June 2005.


Its principal products include:


  * The ChromoliteTM, a safe and effective intense pulsed light device for
    treating unwanted hair, skin pigmentation and thread vein removal.  The
    Chromolite received FDA-approval in January 2006 to distribute its products
    in the US.


  * The NLiteTM-V, a patented pulsed-dye laser system initially developed to
    treat vascular lesions, but proven it to be equally effective in treating
    Acne Vulgaris (the world's commonest skin disease), psoriasis, which affects
    3% of the population and also skin rejuvenation by rebuilding collagen in
    the skin.


  * 'Smoothshapes(R) 100' is a painless, non-invasive laser-based system that
    works gradually and effectively to improve the appearance of cellulite.


  * Nicolite is a laser system targeting smoking cessation which uses a
    coherent beam of light of low power to stimulate the release of endorphins
    by the body.


Chromogenex's products are technically advanced and are well protected by
sufficient patent protection.  The current range is clinically proven and
conforms to the most stringent medical standards.  Its products are also
supported by world-leading luminaries in dermatology, including Dr Tony Chu, a
leading UK authority on acne.  In October 2003, Dr Chu published positive
results of his clinical trials in the Lancet proving the efficacy of NLiteTM-V
for the treatment of Acne Vulgaris.


The medical and aesthetic marketplace is a multi-billion dollar market, the acne
sector alone being estimated at around five billion dollars.  Chromogenex is
well positioned to exploit this massive and ever increasing area.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PRLSEUFEESWSEDM

Chromogenex (LSE:CGX)
Historical Stock Chart
From May 2024 to Jun 2024

Chromogenex (LSE:CGX)
Historical Stock Chart
From Jun 2023 to Jun 2024